ClinicalTrials.gg
Not yet recruitingNCT07939971Updated Nov 16, 2026

A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML

A Phase 1/2 interventional study of TBS-2025 in Acute Myeloid Leukemia, sponsored by TuHURA Biosciences, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by TuHURA Biosciences, Inc. · Phase 1/2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this interventional study is to learn if TBS-2025 is safe to administer to participants with relapsed/refractory (r/r) Acute Myeloid Leukemia (AML). The main questions it aims to answer are:

  • What medical problems do adult participants have when taking TBS-2025?
  • What does the body do from the time TBS-2025 enters the body until it is completely gone?
  • What is the best dose of TBS-2025 to give to participants?
  • Does TBS-2025 work to treat r/r AML?

Participants will:

  • Take TBS-2025 every 2 weeks
  • Visit the clinic every 1 to 2 weeks for checkups and tests
Read the detailed description

This is an open label Phase 1b study evaluating the safety, tolerability, PK, PD, and preliminary efficacy of TBS-2025 in adult patients with r/r NPM1-mutant (r/r defined as per ELN2022) that is resistant to or has relapsed following approved therapies (or are intolerant) and for whom there are no suitable effective therapies. The study is composed of sequential cohorts: a D-E Monotherapy Cohort to assess multiple dose levels and a D-O Monotherapy Cohort to further assess the optimal dose in at least 2 randomly assigned groups.

02

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • acute myeloid leukemia
  • NMP1
  • relapsed
  • refractory
  • VISTA
  • TBS-2025
  • Phase 1b
  • NMP1 mutant
03

In context

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

This study's planned enrollment of 55 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

TuHURA Biosciences, Inc. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented r/r AML (BM blasts ≥5%) with NPM1-mutation
  • Received, and has progressed, recurred, or is intolerant of approved/effective therapeutic options, including treatment with a menin inhibitor, for r/r AML, or declines treatment with these therapies. disease is defined as >5% leukemic blasts in the BM, reappearance of leukemic blasts in PB in >2 PB samples >1W apart, or development of new extramedullary disease. Refractory disease is defined as not having achieved CR/CRi/CRh after 2 cycles of intensive chemotherapy or 4 cycles of less-intensive therapy.
  • Performance Status of 0 to 2
  • WBC count ≤30,000/mm3

Exclusion criteria

Exclusion Criteria:

  • Has acute promyelocytic leukemia
  • Has known active leukemic involvement or clinical symptoms of leukemic involvement of the CNS. CNS disease adequately treated with at least one negative lumbar puncture prior to dosing is acceptable.
  • Has received prior allogenic stem cell transplant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    TBS-2025 administered at multiple, escalating dose levels as monotherapy

    Biological: TBS-2025

  • Experimental
    Dose Optimization

    TBS-2025 administered at 2 or more dose levels as monotherapy

    Biological: TBS-2025

Interventions

  • BiologicalTBS-2025

    TBS-2025 is a fully human IgG1-kappa monoclonal antibody that binds specifically to the hVISTA-ECD and blocks interaction with endogenous VISTA ligands.

    Also known as: trovostobart

06

What researchers measure

Primary outcomes

  1. Number of participants with dose limiting toxicities (DLTs)

    Time frame: At the end of Cycle 1 ( each cycle is 28 days)

  2. Number of participants with an AE

    Time frame: Baseline through study completion, an average of 2 years

Secondary outcomes

  1. Pharmacokinetic (PK) Serum Concentration of TBS-2025

    Time frame: Baseline through the start of Cycle 4 (each cycle is 28 days)

  2. Number of participants with anti-TBS-2025 antibody formation

    Time frame: Baseline through the end of Cycle 4 (each cycle is 28 days)

  3. Rate of Complete Remission

    Time frame: Baseline to study completion, an average of 2 years

  4. Duration of Response

    Time frame: Baseline to study completion, an average of 2 years

  5. Time to Response

    Time frame: Baseline to study completion, an average of 2 years

  6. Morphological Leukemia Free State Rate

    Time frame: Baseline to study completion, an average of 2 years

  7. Rate of Composite Complete Remission

    Time frame: Baseline to study completion, an average of 2 years

  8. Overall Response Rate

    Time frame: Baseline to study completion, an average of 2 years

  9. Event-Free Survival

    Time frame: Baseline to study completion, an average of 2 years

  10. Minimal Residual Disease Negativity Rate

    Time frame: Baseline to study completion, an average of 2 years

  11. Overall Survival

    Time frame: Baseline to study completion, an average of 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 24 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939971
Lead sponsor
TuHURA Biosciences, Inc.
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

James A. Bianco, MD
Contact
clinicaltrials@tuhurabio.com
813-875-6600 ext 104
James A. Bianco, MD
study director · TuHURA Biosciences, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion